Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472649 | 0.92 | UTS2R (0.60) | UTS2RSIGMAR1SMN1; SMN2MAPK1POLB | |
| SCHEMBL1472428 | 0.92 | UTS2R (0.59) | UTS2RSMN1; SMN2MAPK1L3MBTL1POLB | |
| SCHEMBL1474447 | 0.90 | UTS2R (0.72) | UTS2RSMN1; SMN2MAPK1L3MBTL1POLB | |
| SCHEMBL1474448 | 0.90 | UTS2R (0.72) | UTS2RSMN1; SMN2MAPK1L3MBTL1POLB | |
| SCHEMBL1472042 | 0.87 | UTS2R (0.54) | UTS2RSIGMAR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL1472385 | 0.87 | UTS2R (0.53) | UTS2RSIGMAR1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL1472875 | 0.86 | UTS2R (0.73) | UTS2RSIGMAR1TDP1 | |
| SCHEMBL1472073 | 0.85 | UTS2R (0.51) | UTS2RSIGMAR1POLBMEN1ALDH1A1 | |
| SCHEMBL12750494 | 0.85 | UTS2R (0.51) | UTS2RMAPK1MAPTKDM4EMEN1 | |
| SCHEMBL1472930 | 0.83 | UTS2R (1.00) | UTS2RL3MBTL1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | claimed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| CN-102762227-A | Endothelin antibodies | TRACON PHARMACEUTICALS INC | 2012-10-31 | — | — | CN | disclosed |
| CN-102711809-A | Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents | TRACON PHARMACEUTICALS INC | 2012-10-03 | — | — | CN | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-7745645-B2 | Sulfonamide derivatives of xanthene compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090275145-A1 | METAL-ENHANCED FLUORESCENCE FOR POLARIZATION-BASED AFFINITY ASSAYS | UNIVERSITY OF MARYLAND (US) | 2009-11-05 | — | — | US | disclosed |
| US-20080177086-A1 | Sulfonamide Derivatives of Xanthene Compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1947095-A1 | Sulfonamide derivatives of xanthene compounds useful as fluorescent detection reagents | Pierce Biotechnolgoy, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177086-A1 | Sulfonamide Derivatives of Xanthene Compounds | NR2E3, NR0B2, NR2C2 | UTS2R 1601/4885SIGMAR1 549/4885SMN1; SMN2 2599/4885 |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SIGMAR1 2025/4885SMN1; SMN2 2074/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SIGMAR1 2025/4885SMN1; SMN2 2074/4885 |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885SIGMAR1 2025/4885SMN1; SMN2 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.